NeuroPace Inc. Files 8-K for Regulation FD Disclosure
Ticker: NPCE · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1528287
| Field | Detail |
|---|---|
| Company | Neuropace Inc (NPCE) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
TL;DR
NeuroPace dropped an 8-K, likely with material info. Check it out.
AI Summary
On January 15, 2025, NeuroPace Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure, indicating that the company has made material non-public information available to the public. Specific details regarding the nature of this disclosure are not provided in the excerpt.
Why It Matters
This filing signals that NeuroPace Inc. has publicly disseminated important information, which could impact investor decisions. Investors should review the full filing to understand the disclosed material.
Risk Assessment
Risk Level: medium — The filing itself is a procedural notification, but the underlying Regulation FD disclosure could contain significant news impacting the company's stock.
Key Numbers
- 6502372700 — Phone Number (Registrant's telephone number)
Key Players & Entities
- NeuroPace Inc. (company) — Registrant
- January 15, 2025 (date) — Date of earliest event reported
- 455 N. Bernardo Avenue, Mountain View, CA 94043 (address) — Principal executive offices
- 001-40337 (company_id) — Commission File Number
FAQ
What specific information was disclosed under Regulation FD?
The provided excerpt does not specify the content of the Regulation FD disclosure, only that it occurred on January 15, 2025.
What is the purpose of a Regulation FD Disclosure?
A Regulation FD Disclosure is filed when a public company has made material non-public information available to the public, ensuring fair disclosure to all investors.
When was this 8-K report filed?
The report was filed as of January 15, 2025.
What is NeuroPace Inc.'s primary business according to the SIC code?
NeuroPace Inc. is classified under SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus.
Where are NeuroPace Inc.'s principal executive offices located?
NeuroPace Inc.'s principal executive offices are located at 455 N. Bernardo Avenue, Mountain View, CA 94043.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-15 16:43:11
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NPCE The Nasdaq
Filing Documents
- d919201d8k.htm (8-K) — 23KB
- 0001193125-25-007085.txt ( ) — 142KB
- npce-20250115.xsd (EX-101.SCH) — 3KB
- npce-20250115_lab.xml (EX-101.LAB) — 18KB
- npce-20250115_pre.xml (EX-101.PRE) — 11KB
- d919201d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NeuroPace, Inc. Dated: January 15, 2025 By: /s/ Rebecca Kuhn Rebecca Kuhn Chief Financial Officer and Vice President, Finance and Administration